mdl-100907 and Weight-Loss

mdl-100907 has been researched along with Weight-Loss* in 1 studies

Reviews

1 review(s) available for mdl-100907 and Weight-Loss

ArticleYear
Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.
    Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:8

    Lorcaserin is a serotonin 2C receptor antagonist that was FDA approved in 2012. Lorcaserin is recently available as an extended-release (ER) formulation for the treatment of obesity as an adjunct to lifestyle modification. Areas covered: The pharmacokinetics, pharmacodynamics, efficacy, and safety of lorcaserin ER will be reviewed. Expert opinion: Lorcaserin ER 20mg daily provides drug exposure bioequivalent to lorcaserin immediate release (IR) 10mg twice daily. Lorcaserin IR is associated with 3.3 and 3.0% placebo-subtracted weight loss in patients without and with diabetes, respectively. A1C was reduced by 0.9% in patients with diabetes. Common side effects include headache, dry mouth, constipation, dizziness, fatigue, and nausea. Lorcaserin provides potential advantages over other antiobesity medications in regards to tolerability and simplicity of medication initiation, but may not be as effective as other options. Lorcaserin ER offers improved ease of administration and anticipated adherence compared to the IR formulation. The place in therapy for lorcaserin ER and other antiobesity medications will be further clarified by results of pending clinical trials addressing cardiovascular outcomes as well as the role pharmacogenomics and comorbid disease states may play in choosing patient-specific therapy.

    Topics: Anti-Obesity Agents; Benzazepines; Delayed-Action Preparations; Humans; Medication Adherence; Obesity; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Weight Loss

2017